Raushan T Kurmasheva

  • 1479 Citations
  • 22 h-Index
20052020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Raushan T Kurmasheva is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 1479 Citations
  • 22 h-Index
  • 62 Article
  • 6 Review article
  • 2 Short survey
  • 1 Chapter

Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium

Kurmasheva, R. T., Bandyopadhyay, A., Favours, E., Pozo, V. D., Ghilu, S., Phelps, D. A., McGeehan, G. M., Erickson, S. W., Smith, M. A. & Houghton, P. J., Jul 1 2020, In : Pediatric Blood and Cancer. 67, 7, e28284.

Research output: Contribution to journalArticle

  • Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium

    Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., Gatto, G., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., Kolb, E. A. & Gorlick, R., Jun 1 2020, In : Pediatric Blood and Cancer. 67, 6, e28222.

    Research output: Contribution to journalArticle

  • Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

    Kolb, E. A., Houghton, P. J., Kurmasheva, R. T., Mosse, Y. P., Maris, J. M., Erickson, S. W., Guo, Y., Teicher, B. A., Smith, M. A. & Gorlick, R., May 1 2020, In : Pediatric Blood and Cancer. 67, 5, e28098.

    Research output: Contribution to journalArticle

  • Prospective use of the single-mouse experimental design for the evaluation of PLX038A

    Ghilu, S., Li, Q., Fontaine, S. D., Santi, D. V., Kurmasheva, R. T., Zheng, S. & Houghton, P. J., Feb 1 2020, In : Cancer chemotherapy and pharmacology. 85, 2, p. 251-263 13 p.

    Research output: Contribution to journalArticle

  • Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

    Lowery, C. D., Dowless, M., Renschler, M., Blosser, W., VanWye, A. B., Stephens, J. R., Iversen, P. W., Lin, A. B., Beckmann, R. P., Krytska, K., Cole, K. A., Maris, J. M., Hawkins, D. S., Rubin, B. P., Kurmasheva, R. T., Houghton, P. J., Gorlick, R., Anders Kolb, E., Kang, M. H., Patrick Reynolds, C. & 4 others, Erickson, S. W., Teicher, B. A., Smith, M. A. & Stancato, L. F., Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2278-2289 12 p.

    Research output: Contribution to journalArticle

  • 10 Scopus citations